N-carbamimidoyl-1-isoquinolin-1-ylpyrrole-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: N-carbamimidoyl-1-isoquinolin-1-ylpyrrole-3-carboxamide
• 化学式: C₁₅H₁₃N₅O
• 分子量: 279.3
• InChiKey: BAYIHWUGEGCZIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  99.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040266775A1

  公开（公告）日：2004-12-30

  The present invention relates to 3-guanidinocarbonyl-1-heteroaryl-pyrrole derivatives of formula (I) 1 wherein R 1 to R 3 and Ar are as defined herein, pharmaceutical compositions comprising such derivatives, methods of treatment comprising administering such derivatives, and processes for their preparation.

  本发明涉及式(I)的3-胍基甲酰基-1-杂环基-吡咯衍生物，其中R1至R3和Ar的定义如本文所述，包括这种衍生物的制药组合物，包括通过给予这种衍生物的治疗方法，以及它们的制备过程。
• US7078414B2
  申请人：——

  公开号：US7078414B2

  公开（公告）日：2006-07-18
• [EN] DERIVATIVES OF 3-GUANIDINOCARBONYL-1-HETEROARYL-PYRROLE, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE<br/>[FR] DERIVES DE 3-GUANIDINOCARBONYL-1-HETEROARYL-PYRROLE, PROCEDE DE PREPARATION ET INTERMEDIAIRES UTILISES DANS CE PROCEDE, LEURS UTILISATIONS EN TANT QUE MEDICAMENTS ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：AVENTIS PHARMA GMBH

  公开号：WO2004007478A2

  公开（公告）日：2004-01-22

  The present invention relates to 3-guanidinocarbonyl-1-heteroaryl-pyrrole derivatives of the formula (I) in which R1 to R3 and Ar have the meanings stated in the claims. The inventive compounds are suitable for example as antiarrhythmic medicaments with a cardioprotective component for infarction prophylaxis and infarction treatment and for the treatment of angina pectoris. They also inhibit in a preventive manner the pathophysiological processes associated with the development of ischemia-induced damage, in particular in the triggering of ischemia-induced cardiac arryhthmias and of heart failure.